Key result
Candesartan, but not hydralazine, suppressed proteinuria and prevented the decrease of nephrin expression in a rat model of hypertensive nephropathy.
Why the study?
Does candesartan prevent proteinuria and nephrin loss compared to hydralazine in a hypertensive nephropathy model?
Does candesartan prevent proteinuria and nephrin loss compared to hydralazine in a hypertensive nephropathy model?
Candesartan, but not hydralazine, protects against podocyte injury and proteinuria in hypertensive nephropathy, suggesting these effects are dependent on the angiotensin system rather than mechanical stress.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for nephrin loss in diabetic nephropathy; extends rat model data but requires validation before clinical use.
Proteinuria is considered as an indicator of glomerular podocyte injuries and a major cause of chronic kidney disease. Podocytes include important and functional proteins including nephrin. We previously reported proteinuria and nephrin loss in the podocytes of malignant stroke-prone spontaneous hypertensive rats (MSHRSPs), a hypertensive nephropathy model. At first, we actually confirmed that the nephrin was reduced in the human glomeruli with diabetic nephropathy by immunohistochemistry. These specimens showed the tendency of increased blood pressure. Moreover, to investigate the molecular mechanisms of proteinuria and podocyte injuries, we examined the effects of a vasodilator, hydralazine, and an angiotensin receptor blocker, candesartan hydrochloride on the proteinuria and nephrin expression in MSHRSPs. As results, hydralazine had preventive effects on tubular injuries and renal dysfunction but not on podocyte injuries because hydralazine-treated MSHR developed proteinuria and exhibited nephrin loss from the glomeruli. However, candesartan plays protective functions against proteinuria and the decrease of nephrin in addition to the tubular injuries. Thus, candesartan could significantly suppress podocyte injuries. We conclude that podocyte injuries and proteinuria were dependent on an excessive angiotensin system, not mechanical stress.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2017) studied Hypertensive nephropathy. Candesartan vs. Hydralazine was evaluated on Proteinuria and nephrin expression. Candesartan, but not hydralazine, suppressed proteinuria and prevented the decrease of nephrin expression in a rat model of hypertensive nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: